Meeting the Standards of Normal Science in Health Outcomes and Market ccess
Meeting the Standards of Normal Science in Health Outcomes and Market ccess
Meeting the Standards of Normal Science in Health Outcomes and Market Access for Pharmaceutical Products and Devices
Meeting the Standards of Normal Science in Health Outcomes and Market Access for Pharmaceutical Products and Devices

Journal Assessments

A surprising feature of editorial decisions in health technology assessment is the willingness tp publish claims for cost-effectiveness based on the construction of imaginary worlds. This, presumably, means that these journals, Value in Health, Pharmacoeconomics and the Journal of Medical Economics are willing to subscribe to the ‘for approximate information’ meme. Whether the editors recognize the lack of scientific merit in imaginary cost-per-QALY claims and the failure to recognize interval scaling axioms in the construction of lifetime QALYs is an open question. Perhaps the ‘discovery of new facts’ is outside their terms of reference?

 

In the past three years Dr Paul C Langley, Director, Maimon Research has published (together with Dr TG Rhee) a number of systematic reviews of journal content to assess the willingness of these journals to embrace imaginary worlds. These are:

 

Langley PC. Imaginary worlds: Modeled claims for cost-effectiveness published in PharmacoEconomics January 2015 to December 2015. Inov Pharm . 2016;7(2): No. 9.

 

https://pubs.lib.umn.edu/index.php/innovations/article/view/432

 

Langley PC, Rhee TG. Imaginary worlds: A systematic review of the status of modeled cost-effectiveness claims published in the Journal of Medical Economics from January 2015 to December 2015. Inov Pharm . 2016;7(2): No. 16.

 https://pubs.lib.umn.edu/index.php/innovations/article/view/439

Langley PC, Rhee TG. Imaginary worlds: The status of modeled economic evaluation claims published in Value in Health January 2015 to December 2015. Inov Pharm . 2016;7(2): No. 18.

https://pubs.lib.umn.edu/index.php/innovations/article/view/441

 

Langley PC, Rhee T. The Imaginary Worlds of ISPOR: Modeled Cost-Effectiveness Claims Published in Value in Health from January 2016 to December 2016. Inov Pharm. 2017;8(2): No. 14

https://pubs.lib.umn.edu/index.php/innovations/article/view/519

 

 

Langley PC, Rhee TG. More Imaginary Worlds: A Systematic Review of the Status of Modeled Cost-Effectiveness Claims Published in the Journal of Medical Economics from January 2016 to December 2016. Inov Pharm. 2017;8(3): No. 13

 

https://pubs.lib.umn.edu/index.php/innovations/article/view/538

 

Print Print | Sitemap
© Maimon Research LLC